REGN-EB3: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-020-01452-3
Abstract: REGN-EB3 (INMAZEB ® , Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during… read more here.
Keywords: eb3; first approval; regn eb3; ebola virus ... See more keywords